Softgel Healthcare Private Limited

Softgel Healthcare Private Limited, established on October 23, 2003, is a privately held pharmaceutical company headquartered in Pudupakkam, Tamil Nadu, India. The company is registered under the Corporate Identification Number (CIN) U24231TN2003PTC051829 and is classified as a non-government company. As of the latest available data, Softgel Healthcare has an authorized share capital of ₹40 crore and a paid-up capital of ₹29.96 crore. The company's registered office is located at Survey No. 20/1, Vandalur – Kelambakkam Road, Pudupakkam Village, Chengalpattu District, Tamil Nadu, India – 603103.

Softgel Healthcare specializes in the manufacture of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories. The company's product portfolio is concentrated, with the top five products accounting for 99.6% of its total export value. In the fiscal year 2022-2026, the company reported a total export value of $11.5 million USD from 238 shipments, exporting six products across four therapeutic categories. The top five products by export value are Vitamin ($6.8 million, 4.8% market share), Acetaminophen ($2.1 million, 0.9% market share), Dextromethorphan ($1.1 million, 7.4% market share), Phenylephrine ($1.1 million, 1.2% market share), and Omega ($316,000, 1.7% market share).

Softgel Healthcare operates a manufacturing facility located at Survey No. 20/1, Vandalur – Kelambakkam Road, Pudupakkam Village, Chengalpattu District, Tamil Nadu, India – 603103. The facility is equipped to produce a range of pharmaceutical dosage forms, including tablets, capsules, syrups, and injections. The company's manufacturing capabilities are supported by a dedicated Research & Innovation Centre (SRIC), inaugurated on February 5, 2026, at the Crescent Innovation and Incubation Council (CIIC), BSA Crescent Institute of Science and Technology, Chennai. The SRIC is designed to accelerate research and development across complex dosage forms, high-potent formulations, and differentiated delivery platforms, enabling faster and more reliable translation from concept to market.

As of April 2025, the key leadership at Softgel Healthcare includes:

• Surendra Kumar Polavarapu: Chief Executive Officer (CEO), appointed on April 3, 2025.

• Vishal Sharma: Director, appointed on September 12, 2022.

• Arjun Oberoi: Director, appointed on September 12, 2022.

• Sulaiman Abdulhai Mohammed: Director, appointed on September 12, 2022.

• Jaipal Singh Bhagavan Singh: Whole-Time Director, appointed on August 7, 2021.

• Puncham Mukim: Director, appointed on September 12, 2022.

These leaders are responsible for steering the company's strategic direction and operational excellence.

Softgel Healthcare has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for several of its products, such as Acetaminophen, Dextromethorphan Hydrobromide, and Doxylamine Succinate, which are listed in the FDA's database as of January 29, 2026. This indicates that Softgel Healthcare's products are accessible in the U.S. market. Additionally, the company's product portfolio includes items like Enzalutamide, Cyclosporine, Tafamidis, Nintedanib, and Ibuprofen, which are commonly used in various therapeutic areas and are subject to regulatory approvals in these markets. (fda.report)

While specific details regarding approvals in the European Union, United Kingdom, Australia, and Japan are not explicitly available, the company's focus on obtaining necessary certifications and approvals suggests a strategic approach to entering these markets. The establishment of the Research & Innovation Centre (SRIC) in February 2026 underscores Softgel Healthcare's commitment to enhancing its product development capabilities, which is crucial for meeting the stringent regulatory requirements of these regions.

Softgel Healthcare has demonstrated a proactive approach in penetrating emerging markets across Africa, Latin America, and Southeast Asia. The company's product portfolio includes a range of over-the-counter (OTC) medications and nutritional supplements, which are in demand in these regions. For instance, products like Acetaminophen, Dextromethorphan, and Phenylephrine are commonly used for pain relief and cough management, aligning with the healthcare needs of these markets.

The establishment of the SRIC in February 2026 is expected to bolster Softgel Healthcare's ability to develop products tailored to the specific needs of these emerging markets. By focusing on high-potent formulations and differentiated delivery platforms, the company aims to address the unique health challenges prevalent in these regions, thereby enhancing its market penetration and competitiveness.

Softgel Healthcare's geographic strategy reflects a balanced approach to market diversification and risk management. The company's significant export value of $11.5 million USD over 238 shipments indicates a robust presence in international markets. The concentration of 99.6% of its export value in the top five products suggests a focused product strategy, which can lead to operational efficiencies and brand recognition.

However, this concentration also exposes the company to risks associated with market fluctuations and regulatory changes affecting these key products. To mitigate such risks, Softgel Healthcare is investing in its R&D capabilities, as evidenced by the inauguration of the SRIC in February 2026. This initiative aims to diversify the product portfolio and enhance the company's adaptability to changing market dynamics.

Softgel Healthcare has made notable progress in obtaining approvals from the U.S. Food and Drug Administration (FDA). As of January 29, 2026, the FDA's database lists several of the company's products, including Acetaminophen, Dextromethorphan Hydrobromide, and Doxylamine Succinate, indicating that these products are authorized for sale in the U.S. market. (fda.report)

The company's commitment to meeting FDA standards is further demonstrated by its active engagement in the regulatory process, with multiple product listings in the FDA's database. This proactive approach not only facilitates market entry but also underscores Softgel Healthcare's dedication to quality and compliance with international regulatory requirements. (fda.report)

While specific details regarding the World Health Organization (WHO) prequalification and European Union Good Manufacturing Practice (EU GMP) certifications are not explicitly available, Softgel Healthcare's focus on obtaining necessary certifications and approvals suggests a strategic approach to entering these markets. The establishment of the Research & Innovation Centre (SRIC) in February 2026 underscores Softgel Healthcare's commitment to enhancing its product development capabilities, which is crucial for meeting the stringent regulatory requirements of these regions.

Softgel Healthcare operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility is registered with the CDSCO, ensuring compliance with national standards for pharmaceutical manufacturing. Additionally, the company's products are subject to approvals from state drug controllers and export No Objection Certificates (NOCs), which are essential for international trade. The establishment of the SRIC in February 2026 is expected to further strengthen the company's compliance with both domestic and international regulatory standards.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Softgel Healthcare by regulatory authorities. The company's proactive approach to regulatory compliance, as evidenced by its product listings in the FDA's database and the establishment of the SRIC, suggests a commitment to maintaining high standards of quality and compliance. (fda.report)

Softgel Healthcare operates in a competitive pharmaceutical market, with several key players offering similar products and services. Competitors include WuXi AppTec, Eurofins Scientific,